Effect and safety of transcutaneous auricular vagus nerve Stimulation on allergic rhinitis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076586

Enrollment

Unknown

Registered

2023-10-12

Start date

2023-11-01

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

control group:Nasal corticosteroids +H1 antihistamines + sham taVNS

experimental group:transcutaneous auricular vagal nerve stimulation +Nasal corticosteroids +H1 antihistamines

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Meets the diagnostic criteria for allergic rhinitis described in the Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition) (2)Male or female, aged 18-65 (3)Normal consciousness, behavior coordination, no other chronic diseases or mental diseases (4)deemed suitable for this study by the principal investigator (5)Sign the informed consent form and commit to complete the entire follow-up process.

Exclusion criteria

Exclusion criteria: (1)Accompanied by acute and chronic nasosinusitis, otitis media and other ear, nose and throat infectious diseases; (2)6 Sinus/nasal surgery within months (3)Drug-induced rhinitis, chronic epistaxis (4)Anatomic abnormalities with severe deviation of nasal septum that significantly affect respiration (5)Severe respiratory, hematopoietic, cardiovascular or psychiatric disorders (6)Pregnant or lactating women with skin ulcers, contact dermatitis and other skin diseases (7)Glucocorticoid-dependent patients receiving systemic corticosteroids within the past 4 weeks or allergen-specific immunotherapy within 6 months (8)Ongoing or previous immunotherapy (9)Having an implant (e.g. cochlear implant, vagus nerve stimulator, cardiac pacemaker) (10)Other circumstances that, in the opinion of the investigator, may have contributed to a barrier to subject registration

Design outcomes

Primary

Measure	Time frame
Total nasal symptom score;	—

Secondary

Measure	Time frame
Total efficiency;Total Ocular symptom score;Rhinoconjunctivitis Quality of Life Questionnaire;Rhinoscopic Assessment Scale;adverse events;Serum inflammatory factors;	—

Countries

China

Contacts

Public ContactLiu Yehai

The First Affiliated Hospital of Anhui Medical University

liuyehai616@qq.com+86 138 5690 6986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026